382 related articles for article (PubMed ID: 37446024)
41. Characterization of a miRNA Signature with Enhanced Diagnostic and Prognostic Power for Patients with Bladder Carcinoma.
Samara M; Vlachostergios PJ; Thodou E; Zachos I; Mitrakas L; Evmorfopoulos K; Tzortzis V; Giakountis A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003433
[TBL] [Abstract][Full Text] [Related]
42. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
[TBL] [Abstract][Full Text] [Related]
43. Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?
Tonyali S; Yazici S
Int Urol Nephrol; 2016 May; 48(5):671-80. PubMed ID: 26843415
[TBL] [Abstract][Full Text] [Related]
44. MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic tool for muscle-invasive bladder cancer.
Baumgart S; Meschkat P; Edelmann P; Heinzelmann J; Pryalukhin A; Bohle R; Heinzelbecker J; Stöckle M; Junker K
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2725-2736. PubMed ID: 31552489
[TBL] [Abstract][Full Text] [Related]
45. The translational potential of microRNAs as biofluid markers of urological tumours.
Fendler A; Stephan C; Yousef GM; Kristiansen G; Jung K
Nat Rev Urol; 2016 Dec; 13(12):734-752. PubMed ID: 27804986
[TBL] [Abstract][Full Text] [Related]
46. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Rose KM; Huelster HL; Meeks JJ; Faltas BM; Sonpavde GP; Lerner SP; Ross JS; Spiess PE; Grass GD; Jain RK; Kamat AM; Vosoughi A; Wang L; Wang X; Li R
Nat Rev Urol; 2023 Jul; 20(7):406-419. PubMed ID: 36977797
[TBL] [Abstract][Full Text] [Related]
47. [De novo urologic tumors in kidney transplant patients].
Rodríguez Faba O; Breda A; Gausa L; Palou J; Villavicencio H
Actas Urol Esp; 2015 Mar; 39(2):122-7. PubMed ID: 24996779
[TBL] [Abstract][Full Text] [Related]
48. TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma.
Mannan R; Taylor AS; Spratt DE; Chinnaiyan AM; Montgomery JS; Brown NA; Mehra R
Pathol Res Pract; 2020 Jan; 216(1):152663. PubMed ID: 31630874
[TBL] [Abstract][Full Text] [Related]
49. Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis.
Jubber I; Shariat SF; Conroy S; Tan WS; Gordon PC; Lotan Y; Messing EM; Stenzl A; Rhijn BV; Kelly JD; Catto JWF; Cumberbatch MG
Eur Urol; 2020 May; 77(5):583-598. PubMed ID: 31791622
[TBL] [Abstract][Full Text] [Related]
50. Non-urothelial and urothelial variants of bladder cancer.
Yu EM; Belay S; Li W; Aragon-Ching JB
Cancer Treat Res Commun; 2022; 33():100661. PubMed ID: 36442362
[TBL] [Abstract][Full Text] [Related]
51. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
53. Patients with periodontitis might increase the risk of urologic cancers: a bidirectional two-sample Mendelian randomization study.
Li B; Lin Y; Yang Y; Wang Z; Shi R; Zheng T; Liao B; Liao G; Huang J
Int Urol Nephrol; 2024 Apr; 56(4):1243-1251. PubMed ID: 38015384
[TBL] [Abstract][Full Text] [Related]
54. Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer.
Wu L; Chaffee KG; Parker AS; Sicotte H; Petersen GM
Tumour Biol; 2015 Sep; 36(10):7431-7. PubMed ID: 25900876
[TBL] [Abstract][Full Text] [Related]
55. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.
Ge G; Peng D; Guan B; Zhou Y; Gong Y; Shi Y; Hao X; Xu Z; Qi J; Lu H; Zhang X; Zhan Y; Li Y; Wu Y; Ding G; Shen Q; He Q; Li X; Zhou L; Ci W
Clin Chem; 2020 Jan; 66(1):188-198. PubMed ID: 31811000
[TBL] [Abstract][Full Text] [Related]
56. Multicenter prospective study validating the efficacy of a quantitative assessment tool for frailty in patients with urological cancers.
Soma O; Hatakeyama S; Okamoto T; Fujita N; Hamano I; Tanaka T; Momota M; Yoneyama T; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Saitoh H; Nakaji S; Suzuki T; Ohyama C
Med Oncol; 2019 Sep; 36(10):88. PubMed ID: 31520152
[TBL] [Abstract][Full Text] [Related]
57. New Progress of Epigenetic Biomarkers in Urological Cancer.
Wu P; Cao Z; Wu S
Dis Markers; 2016; 2016():9864047. PubMed ID: 27594736
[TBL] [Abstract][Full Text] [Related]
58. Nucleic acid-based marker approaches to urologic cancers.
Veltri RW; Makarov DV
Urol Oncol; 2006; 24(6):510-27. PubMed ID: 17138133
[TBL] [Abstract][Full Text] [Related]
59. Urothelial cancer of the urinary bladder: can lessons learned be applied to the upper urinary tract?
Krabbe LM; Hutchinson RC; Margulis V
Minerva Urol Nefrol; 2016 Aug; 68(4):396-408. PubMed ID: 26990295
[TBL] [Abstract][Full Text] [Related]
60. MicroRNAs: Key Players in Bladder Cancer.
Li Q; Wang H; Peng H; Huang Q; Huyan T; Huang Q; Yang H; Shi J
Mol Diagn Ther; 2019 Oct; 23(5):579-601. PubMed ID: 31325035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
